相关实验视频
Updated: May 26, 2025

04:49
Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
367
在Lewy体痴呆症中出现的胆性退化和早期认知症状
Kyung Ah Woo1, Heejung Kim2,3, Ryul Kim1
1Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Dongjak-gu, Seoul, Republic of Korea.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 22, 2025
概括
胆固醇基底前脑退化开始于前性REM睡眠行为障碍,并预测痴呆. 这种基底前脑缩影响认知,并为利维体疾病的干预提供了目标.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
背景情况:
- 孤立的REM睡眠行为障碍 (iRBD) 是莱维体疾病 (LBD) 的关键早期症状,包括帕金森病 (PD) 和莱维体痴呆症 (DLB).
- 在LBD的认知衰退与胆固醇系统功能障碍有关,但这种退化的进展情况尚不清楚.
研究的目的:
- 调查iRBD中胆基底前脑 (cBF) 退化轨迹及其与整个RBD-LBD频谱的认知功能相关.
- 确定cBF缩是否预测iRBD患者的痴呆发展.
主要方法:
- 在92名iRBD参与者 (49名随访扫描) 中使用MRI测量了基线和纵向cBF体积.
- 检查了连续性的认知关联,包括iRBD,PD与可能的RBD,以及DLB与可能的RBD.
- 评估了iRBD中痴呆症基线cBF体积的预测值.
主要成果:
- 在转换为PD或DLB的个人中,cBF量以类似的速度下降.
- 与PD转换器相比,在DLB转换器中缩更为明显.
- 减少cBF体积与注意力,执行功能和记忆力的缺陷相关.
- 基线cBFz-score低于-1.0显著预测iRBD中的痴呆症 (HR=9.57,p=0.009).
结论:
- 胆基底前脑退化是LBD连续体中的早期过程,从iRBD前阶段开始.
- cBF缩与认知障碍有关,并预测iRBD患者未来的痴呆症.
- 这些发现强调了基底前脑作为LBD早期干预的潜在治疗目标.
相关概念视频
Alzheimer's Disease: Overview
425
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
425
Dementia
88
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
88
Parkinson's Disease: Overview
424
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
424
Alzheimer's Disease: Treatment
149
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
149
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Parkinson's Disease: Treatment
185
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
185

